MAP2K4 and MAPK10

Data Source:
HPRD (in vitro)

		MAP2K4	MAPK10
Description		mitogen-activated protein kinase kinase 4	mitogen-activated protein kinase 10
Image
GO Annotations	Cellular Component	Nucleus Cytosol Axon Dendrite Cytoplasm Perikaryon	Nucleus Nucleoplasm Cytoplasm Mitochondrion Cytosol Plasma Membrane
	Molecular Function	Protein Kinase Activity Protein Serine/threonine Kinase Activity MAP Kinase Kinase Activity Protein Tyrosine Kinase Activity Protein Binding ATP Binding JUN Kinase Kinase Activity Mitogen-activated Protein Kinase Kinase Kinase Binding	Protein Serine/threonine Kinase Activity JUN Kinase Activity MAP Kinase Activity MAP Kinase Kinase Activity Protein Binding ATP Binding
	Biological Process	Activation Of MAPK Activity Apoptotic Process Signal Transduction JNK Cascade Activation Of JUN Kinase Activity Response To Wounding Peptidyl-tyrosine Phosphorylation Positive Regulation Of Smooth Muscle Cell Apoptotic Process Fc-epsilon Receptor Signaling Pathway Positive Regulation Of Neuron Apoptotic Process Positive Regulation Of DNA Replication Positive Regulation Of Nitric-oxide Synthase Biosynthetic Process Cell Growth Involved In Cardiac Muscle Cell Development Cellular Response To Mechanical Stimulus Cellular Response To Sorbitol Negative Regulation Of Motor Neuron Apoptotic Process	Activation Of MAPK Activity Protein Phosphorylation Signal Transduction JNK Cascade JUN Phosphorylation Response To Light Stimulus Intracellular Signal Transduction Fc-epsilon Receptor Signaling Pathway Regulation Of Circadian Rhythm Rhythmic Process Regulation Of DNA-binding Transcription Factor Activity
Pathways		Oxidative Stress Induced Senescence Oxidative Stress Induced Senescence FCERI mediated MAPK activation JNK (c-Jun kinases) phosphorylation and activation mediated by activated human TAK1 Uptake and function of anthrax toxins MAP3K8 (TPL2)-dependent MAPK1/3 activation	Oxidative Stress Induced Senescence FCERI mediated MAPK activation JNK (c-Jun kinases) phosphorylation and activation mediated by activated human TAK1 Activation of the AP-1 family of transcription factors
Drugs			Minocycline Pyrazolanthrone Cyclohexyl-{4-[5-(3,4-Dichlorophenyl)-2-Piperidin-4-Yl-3-Propyl-3h-Imidazol-4-Yl]-Pyrimidin-2-Yl}Amine Cyclopropyl-{4-[5-(3,4-Dichlorophenyl)-2-[(1-Methyl)-Piperidin]-4-Yl-3-Propyl-3h-Imidazol-4-Yl]-Pyrimidin-2-Yl}Amine 9-(4-Hydroxyphenyl)-2,7-Phenanthroline Phosphoaminophosphonic Acid-Adenylate Ester N-(tert-butyl)-4-[5-(pyridin-2-ylamino)quinolin-3-yl]benzenesulfonamide N-BENZYL-4-[4-(3-CHLOROPHENYL)-1H-PYRAZOL-3-YL]-1H-PYRROLE-2-CARBOXAMIDE N-(3-cyano-4,5,6,7-tetrahydro-1-benzothien-2-yl)-2-fluorobenzamide 4-{[5-chloro-4-(1H-indol-3-yl)pyrimidin-2-yl]amino}-N-ethylpiperidine-1-carboxamide (3Z)-1-[(6-fluoro-4H-1,3-benzodioxin-8-yl)methyl]-4-[(E)-2-phenylethenyl]-1H-indole-2,3-dione 3-oxime (3E)-5-fluoro-1-[(6-fluoro-4H-1,3-benzodioxin-8-yl)methyl]-1H-indole-2,3-dione 3-oxime (3Z)-1-[(6-fluoro-4H-1,3-benzodioxin-8-yl)methyl]-4-phenyl-1H-indole-2,3-dione 3-oxime 5-bromo-N-(3-chloro-2-(4-(prop-2-ynyl)piperazin-1-yl)phenyl)furan-2-carboxamide N-cyclohexyl-4-imidazo[1,2-a]pyridin-3-yl-N-methylpyrimidin-2-amine N-{2'-[(4-FLUOROPHENYL)AMINO]-4,4'-BIPYRIDIN-2-YL}-4-METHOXYCYCLOHEXANECARBOXAMIDE 2-{4-[(4-imidazo[1,2-a]pyridin-3-ylpyrimidin-2-yl)amino]piperidin-1-yl}-N-methylacetamide 1-(3-bromophenyl)-7-chloro-6-methoxy-3,4-dihydroisoquinoline Fostamatinib Halicin
Diseases
GWAS		Asthma ( 32296059) Electrocardiogram morphology (amplitude at temporal datapoints) ( 32916098) Estimated glomerular filtration rate ( 31152163) Response to amphetamines ( 22952603)	Cleft lip with or without cleft palate x maternal periconceptional smoking interaction (parent of origin effect) ( 31372216) Cobalt levels ( 26025379) Diisocyanate-induced asthma ( 25918132) Gait speed in old age ( 28077804) Liver enzyme levels (alanine transaminase) ( 22001757) Multiple sclerosis ( 31604244) Peripheral artery disease ( 25009551) Response to cytidine analogues (gemcitabine) ( 24483146) Triglyceride levels ( 32203549 32154731)
Interacting Genes		43 interacting genes: AKT1 ALDOB APP ARRB1 ARRB2 CFLAR CYLC2 DUSP22 EFNA4 FBP2 FLNA FLNC GEMIN5 ITCH JUN LRRK2 MAP2K6 MAP3K1 MAP3K10 MAP3K11 MAP3K12 MAP3K14 MAP3K2 MAP3K20 MAP3K3 MAP3K4 MAP3K5 MAP3K7 MAP3K8 MAP4K2 MAPK1 MAPK10 MAPK12 MAPK14 MAPK8 MAPK8IP3 MAPK9 NBR1 RBBP8 SPAG9 STX17 TRIB1 UBC	38 interacting genes: APP ARRB1 ARRB2 ATF2 BCL2L11 CDK5 CDKN1B CDKN2A CDKN2C CEP290 CREBBP DUSP10 DUSP16 DUSP9 ELK1 FBXO7 GTF3C1 HAX1 HDAC9 HNRNPK HRAS JUN KIF26A LDHA MAP2K4 MAPK8IP2 MAPK8IP3 MAPKBP1 MAPT MCL1 PKMYT1 PLIN2 RELA SH3BP5 STMN2 TNIP1 TP53 UNC119
Entrez ID		6416	5602
HPRD ID		03213	04207
Ensembl ID		ENSG00000065559	ENSG00000109339
Uniprot IDs		P45985	A0A1P0B7D2 A0A286YEQ7 A0A286YES0 A0A286YF02 A0A286YF97 A0A286YFD7 A0A286YFN2 D6RCB1 D6RJF9 F8W9R5 I6L9F3 P53779 Q499Y8
PDB IDs		3ALN 3ALO 3VUT	1JNK 1PMN 1PMU 1PMV 2B1P 2EXC 2O0U 2O2U 2OK1 2P33 2R9S 2WAJ 2ZDT 2ZDU 3CGF 3CGO 3DA6 3FI2 3FI3 3FV8 3G90 3G9L 3G9N 3KVX 3OXI 3OY1 3PTG 3RTP 3TTI 3TTJ 3V6R 3V6S 4H36 4H39 4H3B 4KKE 4KKG 4KKH 4U79 4W4V 4W4W 4W4X 4W4Y 4WHZ 4X21 4Y46 4Y5H 4Z9L 6EKD 6EMH 6EQ9
Enriched GO Terms of Interacting Partners?
Tagcloud ?
Tagcloud (Difference) ?
Tagcloud (Intersection) ?